logo
  

Autodesk Lifts FY22 Outlook; Stock Up 6%

While reporting its results for the second quarter on Wednesday, Autodesk Inc. (ADSK) lifted its outlook for the full year, sending its shares up 6% in after-hours.

Looking forward, the company now expects earnings of $3.40 to $3.59 per share, adjusted earnings of $6.52 to $6.71 per share and revenues of $4.99 billion to $5.04 billion.

Previously, the company expected earnings of $3.24 to $3.47 per share, adjusted earnings of $6.43 to $6.66 per share and revenues of $4.96 billion to $5.06 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $6.54 per share and revenues of $5.01 billion.

"Demand remained robust, our competitive performance strong, and subscription business resilient during the second quarter," said Debbie Clifford, Autodesk CFO. "With the underlying momentum of the business offsetting incremental foreign exchange headwinds, our guidance is unchanged at the mid-point across all metrics. We remain well on track to achieve our fiscal 23 goals."

ADSK closed Wednesday's trading at $214.43, up $0.80 or 0.37%, on the Nasdaq. The stock further gained $13.72 or 6.40% in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
RELATED NEWS
Follow RTT